Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Melanoma 19 Colorectal Neoplasms 11 Brain Neoplasms 7 Colonic Neoplasms 5 Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Rectal Neoplasms 2 Lung Neoplasms 2 Thyroid Neoplasms 1 Solid Tumor 1 Skin Neoplasms 1 Recurrence 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphatic Metastasis 1 Leukemia, Hairy Cell 1 Hematologic Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Astrocytoma 1

Interventions

Temozolomide 46 Radiotherapy 36 Bevacizumab 34 Carmustine 13 Erlotinib Hydrochloride 11 Irinotecan 10 sargramostim 7 Thalidomide 7 Chemotherapy, Adjuvant 7 Carboplatin 7 Radiation 6 pembrolizumab 5 Topotecan 5 Magnetic Resonance Spectroscopy 5 Filgrastim 5 Drug Therapy 5 Cyclophosphamide 5 aldesleukin 4 Tamoxifen 4 Surgical Procedures, Operative 4 Sorafenib 4 O(6)-benzylguanine 4 Gefitinib 4 Etoposide 4 Celecoxib 4 cediranib 3 Radiotherapy, Intensity-Modulated 3 Radiotherapy, Conformal 3 Peripheral Blood Stem Cell Transplantation 3 Imatinib Mesylate 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Gliosarcoma × encorafenib × Clear all

NCT03973918 2024-10-31

BRAF

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated

5 enrolled 15 charts

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡